Branched Chain Amino Acids for Sarcopenia in Patients Undergoing Total Knee Arthroplasty

Inclusion criteria

• Patients aged 40 to 100 years who are scheduled to undergo total knee arthroplasty.

Exclusion criteria

• Participants who used antiretroviral agents within 4 weeks before the first administration of Livact.
• Participants who used medications associated with fatty liver within 4 weeks before the first administration of Livact, including thiazolidinediones, sodium glucose cotransporter 2 inhibitors, amiodarone, methotrexate, tamoxifen, valproate, or corticosteroids.
• Participants who used branched chain amino acid products or multinutritional supplements within 4 weeks before the first administration of Livact.
• Participants who used pain medications other than those prescribed for total knee arthroplasty treatment within 2 weeks before the first administration of Livact.
• Participants with markedly decreased hepatic protein synthetic function.
• Participants with congenital branched chain amino acid metabolism disorders.
• Participants with hereditary galactose intolerance, Lapp lactase deficiency, or glucose galactose malabsorption.
• Participants with a history of high tibial osteotomy.
• Participants with neurologic diseases such as stroke or Parkinson disease.
• Participants with gait disturbance due to causes other than arthritis.
• Participants taking medication for spinal stenosis.
• Participants with a history of hypersensitivity to the investigational product or its components.
• Pregnant or breastfeeding participants.
• Participants planning pregnancy during the trial or who have the possibility of pregnancy but do not agree to use appropriate contraception during the trial.
• Participants judged by the investigator to be inappropriate for participation in the clinical trial.